Here's Vertex Willing Premium: Inside the Crinetics Deal
When a pharma giant pays more than double a target’s value, the move sends shockwaves through investors. This article...
Pinpoint root causes, such as leakage or overspending, then implement targeted adjustments to regain monthly balance.
24,154 articlesWhen a pharma giant pays more than double a target’s value, the move sends shockwaves through investors. This article...
A new stake in Vista Energy signals rising institutional interest in the energy sector. This article breaks down why ...
A notable new stake in Kyndryl signals growing confidence from a private equity–style shop. This deep dive explains w...
A major investor sold a substantial stake in an Ethereum ETF, pulling out nearly $19 million in one trade. The move r...
A regional bank stock year delivered a solid 14% gain even as a large investor trimmed holdings by roughly $2.6 milli...
A breakout multiple sclerosis drug can change a biotech's trajectory. This article digs into an $8 million investment...
A rare look at how a mega-charity stewards billions in investments, the risk of concentration, and practical steps yo...
Investors eyes are on Hackett Group as 2026 unfolds. This guide breaks down how to read the Hackett Group (HCKT) 2026...
A hedge fund recently boosted its position in 10x Genomics, highlighting growing confidence in the biotech tools make...
Today’s market moved in Ford’s favor as analysts primed optimism around Ford’s energy initiatives alongside its tradi...
A major private markets investor recently exited its position in Paymentus Holdings, shedding a sizable stake in a mo...
Poet Technologies rose today amid broader AI stock swings. This guide explains what moved the stock, what to watch go...